anti cd157 monoclonal antibody men1112

Drug Overview

The medication known as anti cd157 monoclonal antibody men1112 (also identified as OBT357) is an investigational, humanized monoclonal antibody designed to treat aggressive blood cancers, primarily Acute Myeloid Leukemia (AML). It targets the CD157 antigen (also known as BST1), a protein found on the surface of leukemia cells that is often associated with poor prognosis and resistance to standard treatments.

Developed by Menarini Group in collaboration with Oxford BioTherapeutics, MEN1112 was engineered as a “defucosylated” antibody. This specific modification enhances its ability to recruit the body’s natural killer (NK) cells to attack the cancer more aggressively.

• Generic Name: MEN1112.
• Other Names: OBT357.
• Drug Class: Humanized, Defucosylated Monoclonal Antibody (IgG1).
• Target: CD157 (BST-1 / Bone Marrow Stromal Cell Antigen 1).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Inactive. As of March 2026, MEN1112 is not FDA-approved. The primary clinical trial (ARMY-1, NCT02353143) was terminated. While the drug demonstrated potent biological activity in laboratory settings, unpredictable liver toxicities and limited clinical responses in humans led to the cessation of its clinical development.

What Is It and How Does It Work? (Mechanism of Action)

The CD157 Target

CD157 is a protein belonging to the ADP-ribosyl cyclase family. It is expressed in approximately 91% to 97% of AML patient samples, particularly at the time of relapse. Because it is highly present on leukemia “blasts” but has restricted expression on healthy cells, it was identified as a promising target for precision therapy.

Molecular Level Mechanisms

1. High-Affinity Binding: Once infused, MEN1112 circulates and binds specifically to the CD157 antigen on the surface of AML cells.
2. Fc-Engineered Recruitment: The antibody is “defucosylated,” meaning a specific sugar molecule is removed from its structure. This modification increases its affinity for the Fc$\gamma$RIIIa receptor on Natural Killer (NK) cells.
3. Immune-Mediated Lysis: By bridging the leukemia cell and the NK cell, MEN1112 triggers the NK cell to release toxic proteins (perforins and granzymes). These proteins poke holes in the leukemia cell membrane, causing it to burst and die (lysis).
4. Independence from Genetic Variation: Because of its engineered design, MEN1112’s effectiveness is not hindered by the common $Fc\gamma R$ polymorphisms that often make other monoclonal antibodies less effective in certain patients.

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for MEN1112.

During its clinical life, it was investigated in a first-in-human study for:

• Relapsed or Refractory Acute Myeloid Leukemia (AML): Targeted at adult patients who had failed standard induction therapy or hypomethylating agents.

Dosage and Administration Protocols

Because the drug was discontinued during Phase I, there is no established “Standard of Care” dose. The following were the protocols established during the ARMY-1 trial.

Clinical Efficacy and Research Results

The clinical results for MEN1112 serve as a significant case study in the challenges of targeting CD157.

• Preclinical Success: Ex vivo assays showed that MEN1112 could successfully deplete AML blasts in about 46% of cases in peripheral blood and 36% of cases in bone marrow.
• Trial Termination (ARMY-1): The Phase I clinical trial was terminated prematurely. Regulatory reports and subsequent reviews indicated that patients experienced unpredictable liver toxicities that made further dose escalation unsafe.
• Response Rates: Clinical responses in the human subjects were limited, suggesting that while the drug hit its target, it was not powerful enough as a single agent to provide a sustained cure in a relapsed setting.

Safety Profile and Side Effects

The primary barrier to MEN1112’s development was its safety profile, specifically its impact on the liver.

Common Side Effects:

• Fatigue: General tiredness.
• Nausea: Mild and manageable.
• Infusion-Related Reactions (IRRs): Chills and fever during the IV process.

Serious Adverse Events (Dose-Limiting):

• Hepatotoxicity (Liver Toxicity): Unpredictable spikes in liver enzymes and potential liver damage were the primary safety signals that halted the trial.
• Myelosuppression: Significant drops in healthy blood cell counts, a common risk when targeting cells in the bone marrow.

Research Areas

In the field of Stem Cell and Regenerative Medicine, CD157 is studied for its role in the “Vascular Niche.” CD157 is expressed on some vascular endothelial cells and may play a role in how leukemia cells “stick” to blood vessels to hide from chemotherapy. Researchers are using the lessons from MEN1112 to develop Bispecific Antibodies or CAR-T cells that target CD157. The goal is to clear the bone marrow “niche” of resistant cancer cells while using regenerative therapies to protect the healthy blood-forming stem cells.

Patient Management and Practical Recommendations

Pre-treatment Tests (Historically Required):

• CD157 Expression Testing: FACS (flow cytometry) analysis to confirm the presence of the target on tumor cells.
• Baseline Liver Function Tests (LFTs): Critical for monitoring for the drug’s primary toxicity.
• Central Nervous System (CNS) Screening: Active CNS involvement was an exclusion criterion.

Precautions:

• Liver Health Monitoring: Patients in trials required frequent blood work to catch early signs of liver stress.
• White Blood Cell Management: Pre-treatment with hydroxyurea was sometimes used to lower cell counts before the infusion.

“Do’s and Don’ts” List:

• DO report any yellowing of the eyes or skin (jaundice) immediately, as this signals liver issues.
• DO keep track of your daily temperature, as a fever can indicate either an infusion reaction or an infection.
• DON’T ignore sudden abdominal pain on your right side.
• DON’T start any new herbal medications that affect the liver (such as Kava or excessive Tylenol) while on experimental liver-sensitive therapies.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. MEN1112 (OBT357) is an inactive investigational agent and is not FDA-approved. Its development was stopped due to safety and efficacy concerns. Always consult with a qualified hematologist-oncologist regarding currently available and approved treatments for leukemia or active clinical trials.